[18F]MFBG PET/CT 在与 SSTR PET 的前瞻性比较中是神经母细胞瘤有效且更优的显像方式
这项前瞻性双中心研究纳入16例有神经母细胞瘤病史的患者,配对行[18F]MFBG与SSTR靶向PET显像。12例活动期患者两种显像均至少检出1个病灶,4例扫描阴性者经临床随访确认为缓解。基于病灶分析,[18F]MFBG检出292个病灶 vs SSTR PET检出243个(p=0.128),总Curie评分[18F]MFBG显著高于SSTR PET(130 vs 90,p=0.028)。
要点
- [18F]MFBG与SSTR PET在活动期神经母细胞瘤患者中均能检出病灶,诊断效能相当
- [18F]MFBG总Curie评分显著高于SSTR PET(130 vs 90,p=0.028)
- SSTR PET未发现可改变患者管理的独特临床相关发现
核心结论
- 在一对一比较中,[18F]MFBG PET/CT在神经母细胞瘤中显示出与SSTR靶向PET相当的优异诊断效能。
- 作者认为不推荐常规双示踪剂显像,应基于特定治疗考虑(包括[131I]MIBG核素治疗或肽受体放射性核素治疗(PRRT)的临床需要)用于患者。
研究设计与样本
- 前瞻性研究,纳入16例确诊神经母细胞瘤病史的患者(中位年龄5.0岁,IQR 3.3–5.8岁),在两个中心行配对[18F]MFBG与SSTR PET显像。
- SSTR靶向PET使用[68Ga]Ga-DOTATATE或[18F]AlF-NOTA-octreotide([18F]-OC)。
- 按患者和按病灶比较病灶检出率、Curie评分和示踪剂摄取指标。
主要发现
- [18F]MFBG和SSTR PET在全部12例活动期患者中均至少检出1个病灶;4例扫描一致阴性者经临床随访(范围3–13个月)确认处于缓解。
- 基于病灶分析,[18F]MFBG检出292个病灶,SSTR PET检出243个病灶(p=0.128)。
- 总Curie评分[18F]MFBG显著高于SSTR PET(130 vs 90,p=0.028)。
- 在骨髓转移中,[18F]MFBG的SUVmax略低于SSTR PET(8.2 ± 7.8 vs 9.9 ± 6.7,p=0.176),但肿瘤-本底比更高(TBR,12.6 ± 8.6 vs 9.1 ± 5.3,p=0.09)。
- 当[18F]MFBG PET可用时,SSTR PET未独特发现可改变患者管理的临床相关结果。
关键数值与推荐
- 总Curie评分[18F]MFBG 130 vs SSTR PET 90(p=0.028)。
- 病灶检出数[18F]MFBG 292 vs SSTR PET 243(p=0.128)。
- 骨髓转移SUVmax[18F]MFBG 8.2 ± 7.8 vs SSTR PET 9.9 ± 6.7(p=0.176)。
- 骨髓转移TBR[18F]MFBG 12.6 ± 8.6 vs SSTR PET 9.1 ± 5.3(p=0.09)。
临床怎么用
- 作者认为不推荐常规双示踪剂显像,应基于特定治疗考虑(包括[131I]MIBG核素治疗或PRRT的临床需要)用于患者。
- 当[18F]MFBG PET可用时,SSTR PET未独特发现可改变患者管理的临床相关结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [18F]-meta-fluorobenzylguanidine ([18F]MFBG) and somatostatin receptor (SSTR)-targeted PET tracers have both been proposed for imaging neuroblastoma, however, their respective clinical roles remain unclear. This prospective study compared [18F]MFBG PET with SSTR-targeted PET, using either [68Ga]Ga-DOTATATE or [18F]AlF-NOTA-octreotide([18F]-OC), to evaluate diagnostic performance and potential clinical impact in neuroblastoma. METHODS: Sixteen patients (median age 5.0 years, IQR 3.3-5.8 years) with confirmed history of neuroblastoma underwent paired [18F]MFBG and SSTR PET imaging across two centers. Lesion detection rate, Curie scores, and tracer uptake metrics were compared on both a per-patient and per-lesion basis. RESULTS: [18F]MFBG and SSTR PET both identified at least one lesion in all 12 patients with active disease. Four patients had concordant negative scans and were confirmed to be in remission on clinical follow-up (range, 3-13 months). On lesion-based analysis, [18F]MFBG detected 292 lesions, compared to 243 lesions identified by SSTR PET (p = 0.128). Aggregate Curie scores were significantly higher with [18F]MFBG than with SSTR PET (130 vs. 90, p = 0.028). In bone marrow metastases, [18F]MFBG showed slightly lower SUVmax compared to SSTR PET (8.2 ± 7.8 vs. 9.9 ± 6.7, p = 0.176), but yielded a higher tumor-to-background ratio (TBR, 12.6 ± 8.6 vs. 9.1 ± 5.3, p = 0.09). Importantly, no clinically relevant findings were uniquely identified on SSTR PET that altered patient management when [18F]MFBG PET was available. CONCLUSION: In this head-to-head comparison, [18F]MFBG PET/CT demonstrates excellent diagnostic performance in neuroblastoma, comparable to SSTR-targeted PET. These findings suggest that routine dual-tracer imaging is not recommended and should be reserved for patients based on specific therapeutic consideration, including the clinical need for [131I]MIBG radionuclide therapy or peptide receptor radionuclide therapy (PRRT). CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov: NCT05069220 (Registered: 25 September 2021, retrospectively registered); Institute Review Board of Peking Union Medical College Hospital: ZS-2514. CLINICALTRIALS: gov: NCT06852807 (Registered: 24 February 2025, retrospectively registered); Institute Review Board of The First Affiliated Hospital of Zhejiang University School of Medicine: [2025 C] IIT No.008.
引用
- Wang P, Yu S, Chen X, et al. [18F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET. Eur J Nucl Med Mol Imaging. 2025. PMID: 40717185. doi:10.1007/s00259-025-07449-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。